Risk Factors for Adverse Outcomes in Sepsis

NCT06541600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 567

Last updated 2026-05-20

No results posted yet for this study

Summary

This multi-phase prospective study utilized Data-Independent Acquisition proteomics on a nested subset (15 SIC vs. 15 matched sepsis) to map early molecular alterations. Guided by gene-set enrichment evidence of extracellular matrix (ECM) disruption as a pathway-derived biomarker. Admission matrix metalloproteinase-3 was validated in 567 critically ill patients (417 sepsis, 150 non-septic controls) across three hospital campuses.

Conditions

Sponsors & Collaborators

  • Qin Zhang

    lead OTHER

Principal Investigators

  • QIN Zhang, phd · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2024-10-14
Completion
2024-10-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06541600 on ClinicalTrials.gov